Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Natural immunity to pluripotency antigen OCT4 in humans
2010
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
Rheumatoid arthritis
2018 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Pixantrone: a novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma
2015
Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan
2015
Rheumatoid arthritis
2016 Standout
Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective
2009 Standout
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor
2016
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
2011
Brain development in rodents and humans: Identifying benchmarks of maturation and vulnerability to injury across species
2013 Standout
PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma
2016
Pre-Evaluated Safe Human iPSC-Derived Neural Stem Cells Promote Functional Recovery after Spinal Cord Injury in Common Marmoset without Tumorigenicity
2012 StandoutNobel
The impact of differential antiviral immunity in children and adults
2012
FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis
2013
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
Immunogenicity of Induced Pluripotent Stem Cells
2011 StandoutNobel
Peripheral T-cell Lymphomas of Follicular T-Helper Cell Derivation With Hodgkin/Reed-Sternberg Cells of B-cell Lineage
2013
Immunogenicity of induced pluripotent stem cells
2011 StandoutNature
Discovering Disease Associations by Integrating Electronic Clinical Data and Medical Literature
2011
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
2014
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Cardioprotective effect of metoprolol and enalapril in doxorubicin‐treated lymphoma patients: A prospective, parallel‐group, randomized, controlled study with 36‐month follow‐up
2010
Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus–Associated Lymphoma: AIDS Malignancy Consortium Study 020
2007
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs
2015
Prevention of Hepatitis B reactivation in the setting of immunosuppression
2016
Risk stratification for invasive aspergillosis in immunocompromised patients
2012
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Cytotoxic T-cell and NK-cell Lymphomas
2014
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc–positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study
2016
Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders
2016
Mining electronic health records: towards better research applications and clinical care
2012 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
2014 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC
2014
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase
2017
Prevention and Treatment of Cancer-Related Infections
2012
Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis
2015
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision
2017 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Randomized Controlled Trial of Entecavir Prophylaxis for Rituximab-Associated Hepatitis B Virus Reactivation in Patients With Lymphoma and Resolved Hepatitis B
2013
Liposomal Formulations in Clinical Use: An Updated Review
2017 Standout
Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy
2012
Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta‐analysis
2017
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non‐Hodgkin lymphoma: aSIE ,SIES , andGITMO consensus paper
2016
A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
2008
Liposomal daunorubicin as treatment for Kaposi's sarcoma.
2007
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma
2019
Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study
2014
Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation
2016
Works of Soon Thye Lim being referenced
The relationship of hepatitis B virus infection and non‐Hodgkin’s lymphoma and its impact on clinical characteristics and prognosis
2007
Late‐onset neutropenia following RCHOP chemotherapy in diffuse large B‐cell lymphoma
2009
Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?
2005
Angioimmunoblastic T‐cell lymphoma with hyperplastic germinal centres (pattern 1) shows superior survival to patterns 2 and 3: a meta‐analysis of 56 cases
2012
Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines
2013
Non-AIDS-defining cancers and HIV infection
2005
Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis
2011
A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma
2007
Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis
2015
High SUV uptake on FDG–PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG–PET/CT staging in lymphoma
2009
Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy
2009
Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group
2012
A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center
2010
Type II enteropathy‐associated T‐cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group
2012
Weekly docetaxel is safe and effective in the treatment of advanced‐stage acquired immunodeficiency syndrome‐related Kaposi sarcoma
2004
Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT
2017
Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma
2005
Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group
2013
Non—AIDS–Defining cancers and HIV infection
2005
Does the proliferation fraction help identify mature B cell lymphomas with double‐ and triple‐hit translocations?
2012
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
2012
A NEW BCL‐2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST‐IN‐HUMAN STUDY
2017
Angiogenesis and hematological malignancies
2005